



**Australian Government**

**Department of Health**

Therapeutic Goods Administration

# Recall Action Notification

MYLA V4.7 (V4.7.1) and V4.8 (V4.8.1 or V4.8.2). An in vitro diagnostic medical device (IVD)

© Commonwealth of Australia 2021.

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[tga.copyright@tga.gov.au](mailto:tga.copyright@tga.gov.au)>.

## Important information on the System for Australian Recall Actions

The TGA publishes information about therapeutic goods supplied in the Australian market that have been subject to a recall action in a publicly searchable database.

Recall action means action taken by the responsible entity (being the person who is responsible for taking the recall action) to resolve a problem with therapeutic goods supplied in the Australian market that have, or may potentially have, deficiencies relating to safety, quality, efficacy (performance) or presentation.

- Recall actions include: the permanent removal of therapeutic goods from supply in the market, the taking of corrective action in relation to therapeutic goods (such as repair, modification, adjustment or relabelling) and, in the case of medical devices that have been implanted into patients, the issuing of a hazard alert containing information for health practitioners on how to manage patients.
- More information about Australian recall actions is available at <<http://tga.gov.au/safety/recalls-about.htm>>
- If you are taking a medicine, using a medical device or have had a medical device implanted into you, that is the subject to a recall action, and you have any concerns you should seek advice from a health professional. <<http://www.healthdirect.org.au/>>

### About the release of this information

While reasonable care is taken to ensure that the information is an accurate record of recall actions that responsible entities have reported to the TGA or of which the TGA has become aware, the TGA does not guarantee or warrant the accuracy, reliability, completeness or currency of the information or its usefulness in achieving any purpose.

To the fullest extent permitted by law, including but not limited to section 61A of the Therapeutic Goods Act 1989, the TGA will not be liable for any loss, damage, cost or expense incurred in or arising by reason of any person relying on this information.

The information contained in the SARA database is released under s 61(5C) of the Therapeutic Goods Act 1989. Copyright restrictions apply to the System of Australian Recall actions (SARA) <<http://tga.gov.au/about/website-copyright.htm>>.

## Recall detail

<b>Type of Product<sup>i</sup></b>	Medical Device
<b>TGA Recall Reference<sup>ii</sup></b>	RC-2021-RN-02004-1
<b>Product Name/Description<sup>iii</sup></b>	MYLA V4.7 (V4.7.1) and V4.8 (V4.8.1 or V4.8.2). An in vitro diagnostic medical device (IVD)  ARTG 290580 (Biomerieux Australia Pty Ltd - Software IVDs)
<b>Recall Action Level<sup>iv</sup></b>	Hospital
<b>Recall Action Classification<sup>v</sup></b>	Class II
<b>Recall Action Commencement Date<sup>vi</sup></b>	8/10/2021
<b>Responsible Entity<sup>vii</sup></b>	Biomerieux Australia Pty Ltd
<b>Reason / Issue<sup>viii</sup></b>	<p>Following one customer complaint, a MYLA software anomaly has been confirmed that can result in a bottle maximum test time (MTT) being reset to the default MTT. The bottle may then be unloaded before the desired incubation time.</p> <p>This can occur specifically when an identification of a paired bottle is made outside of MYLA and the result is sent back to MYLA from the Laboratory Information System (LIS).</p> <p>This issue could appear if MTT is driven by LIS requests. This issue can't appear if customer is using MTT feature directly through VIRTUO instrument interface.</p>
<b>Recall Action<sup>ix</sup></b>	Product Defect Correction
<b>Recall Action Instructions<sup>x</sup></b>	<p>Biomerieux is advising customers to check if the four required conditions (listed in the letter supplied to impacted end users) are met. If not, customers are not impacted by this anomaly. If yes, customers are advised to contact Biomerieux to receive workarounds aligned with customer workflow.</p> <p>Among tests previously performed, customers should identify any possible false results that may have occurred, to analyze the related risks and to determine appropriate actions if relevant.</p>
<b>Contact Information<sup>xi</sup></b>	1800 333 421 - bioMerieux Helpdesk

## Footnotes

<sup>i</sup> Type of Product: Medicine, Medical Device, or Biological

<sup>ii</sup> TGA Recall Reference: Unique number given by the TGA

<sup>iii</sup> Product Name/Description: Brand name (including active ingredient for medicines) and may include generic reference for the kind of medical devices. Includes all necessary information such as affected: catalogue / model and / or batch / serial numbers.

<sup>iv</sup> Recall Action Level: The level to which the recall action is to be undertaken. This is based on the significance of the risk and the channels through which the goods have been distributed. The recall action levels are / Wholesale / Hospital / Retail / Consumer.

- **Wholesale** - includes wholesalers and state purchasing authorities.
- **Hospital** - includes nursing homes and institutions, hospital pharmacists, ambulance services, blood and tissue banks and laboratories as well as wholesale as appropriate.
- **Retail** - includes retail pharmacists, medical, dental and other health care professionals as well as wholesale and hospital as appropriate.
- **Consumer** - includes patients and consumers, as well as wholesale, hospital and retail levels as appropriate.

<sup>v</sup> Recall Action Classification<sup>\*\*</sup>: Recall actions of therapeutic goods are classified based on the potential risk the deficiency poses to patients / consumers. They are classified as Class I, Class II or Class III.

- **Class I** - A situation in which there is a reasonable probability that the use of, or exposure to, the deficient therapeutic good(s) will cause serious adverse health consequences or death.
- **Class II** - A situation in which use of, or exposure to, the deficient therapeutic good(s) may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- **Class III** - A situation in which use of, or exposure to, the deficient therapeutic good(s) is not likely to cause adverse health consequences.

<sup>vi</sup> Recall Action Commencement Date: The date the recall strategy and communication was agreed by the TGA.

<sup>vii</sup> Responsible Entity: Sponsor / Supplier / Importer responsible for the recall actions.

<sup>viii</sup> Reason / Issue: Reason for the recall action.

<sup>ix</sup> Recall Action<sup>\*\*</sup>: Recall action is an action taken to resolve a problem with a therapeutic good already supplied in the market for which there are issues or deficiencies in relation to safety, quality, efficacy (performance) or presentation.

There are four distinct recall actions – recall, product defect correction, hazard alert and product defect alert.

- **Recall** - The permanent removal of an affected therapeutic good from supply or use in the market.
- **Product defect correction** - Repair, modification, adjustment or re-labelling of a therapeutic good. The corrective action may take place at the user's premises or any other agreed location.
- **Hazard alert** - Information issued to healthcare professionals about issues or deficiencies relating to an implanted medical device or biological product and advice about the ongoing management of patients.
- **Product defect alert** - Information issued to raise awareness about issues or deficiencies for a therapeutic good where a recall action will result in interruption of patient treatment or a medicine shortage, including advice to reduce potential risks of using affected goods.

<sup>x</sup> Recall Action Instructions: What customers with affected goods should do.

<sup>xi</sup> Contact Information: Who the customer should contact for additional information and clarification regarding the recall action.

<sup>\*\*</sup> These definitions are applicable to the 2017 URPTG (Implemented from Jan 15 2018). Recall Action types and Recall Action Classifications prior to 15 Jan 2018 can be found at:

<https://www.tga.gov.au/sites/default/files/recalls-urptg-170412.pdf>